UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report: August 3, 2006
Date of earliest event reported: July 28, 2006
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
1-3619
13-5315170
(State or other Jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
235 East 42nd Street
New York, New York
(Address of principal executive offices)
10017
(Zip Code)
Registrant's telephone number, including area code:
(212) 573-2323
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communication pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 1.01
Entry into a Material Definitive Agreement
On July 28, 2006, the Board of Directors of
Pfizer Inc. ( Pfizer or the Company ) named
Jeffrey B. Kindler Pfizer s Chief Executive Officer effective July
31, 2006. He succeeds Henry A. McKinnell, who will remain Pfizer s
Chairman of the Board of Directors (the Board ) until February
28, 2007, at which time Dr. McKinnell will retire from the Board. Mr.
Kindler has been elected to the Board effective July 31, 2006. A copy
of the press release announcing the change in the Chief Executive Officer
position is attached hereto as Exhibit 99 and is incorporated herein by
reference.
On July 28, 2006, the Compensation Committee of the Board approved new
compensation arrangements for Mr. Kindler. In connection with Mr. Kindler s
promotion to Chief Executive Officer, his base salary was increased from
$947,500 to $1,350,000 and his target annual bonus under the Company s
Executive Annual Incentive Plan was increased from 65% to 150% of base
salary. The Compensation Committee also approved the grant to Mr. Kindler
of an option to purchase 500,000 shares of Pfizer common stock under Pfizer s
2004 Stock Plan at an exercise price of $26.29 per share, the fair market
value of the Pfizer common stock on July 31, 2006. (Special grants are
typically granted at the end of the month of approval with an exercise
price set at the average of the highest and lowest trading price on the
date of grant.) The option will become exercisable upon the fifth anniversary
of the date of grant, provided, however, that the option may not be exercised
unless and until the average closing price of Pfizer common stock for
20 consecutive trading days exceeds 150% of the exercise price. In addition,
the Compensation Committee determined that any amount earned under any
currently outstanding performance-contingent share and performance-share
awards held by Mr. Kindler would be settled through an award of restricted
stock units if the Company s actual total shareholder return achieved
with respect to such award is less than the median total shareholder return
of the Company s pharmaceutical peer group. The restricted stock
units will vest and become payable in shares of Pfizer common stock if
and when the Company s three year total shareholder return based
on the rolling average over a three calendar year period (current calendar
year plus two prior calendar years) exceeds the median for the pharmaceutical
peer group which is described in Pfizer s Definitive Proxy Statement
filed on March 6, 2006. Upon his retirement or other termination of employment,
any unvested restricted stock units will be forfeited. Mr. Kindler and
his spouse and dependent children will be required to use aircraft provided
by the Company for air travel for security reasons.
Item 5.02
Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers
On July 28, 2006, the Board named Jeffrey B.
Kindler Pfizer s Chief Executive Officer effective July 31, 2006.
Mr. Kindler succeeds Henry A. McKinnell as Chief Executive Officer. Dr.
McKinnell will continue to serve as Pfizer s Chairman of the Board
until February 28, 2007.
On July 28, 2006, Mr. Kindler was appointed to the Board effective July
31, 2006. Mr. Kindler was also named Chairman of the Executive Committee
of the Board.
Biographical and Other Information Regarding Mr. Kindler
Mr. Kindler, 51, joined Pfizer in 2002 as senior vice president and general
counsel. He became executive vice president and general counsel in 2004
and vice chairman and general counsel in 2005, leading both the legal
and corporate affairs divisions. Prior to joining Pfizer, Mr. Kindler
served as chairman and chief executive officer of Boston Market Corporation,
owned by McDonald s, and president of Partner Brands, also owned
by McDonald s. He was executive vice president, corporate relations
and general counsel of McDonald s from 1997 to 2001, and from 1996
to 1997 served as that company s senior vice president and general
counsel.
Prior to McDonald s, Mr. Kindler was vice president and senior counsel
for litigation and legal policy for General Electric. A former partner
at the Washington law firm of Williams & Connolly, Mr. Kindler also
served as a law clerk to U.S. Supreme Court Justice William J. Brennan,
Jr. and to Judge David L. Bazelon of the U.S. Court of Appeals for the
D.C. Circuit. He also worked at the Federal Communications Commission.
Mr. Kindler earned his B.A. degree, summa cum laude, from Tufts University
in 1977 and J.D. degree, magna cum laude, from Harvard Law School in 1980,
where he served as an editor of the Harvard Law Review.
The material terms of the compensatory arrangements with Mr. Kindler are
described in Item 1.01 of this Form 8-K and are incorporated herein by
reference.
Departure of Dr. McKinnell
The Company is currently negotiating the definitive terms of Dr. McKinnell s
departure as a principal officer. The Company currently expects that any
amounts and benefits payable to Dr. McKinnell as a result of such negotiations
will not exceed the amounts and benefits he would be entitled to receive
under his employment agreement as if he were terminated without cause
as of February 28, 2007. The Company is in the process of reviewing and
quantifying such amounts and benefits. The material terms of Dr. McKinnell s
employment agreement are described in Pfizer s Definitive Proxy
Statement filed on March 16, 2006 and such description is incorporated
herein by reference. The Company will disclose the definitive terms of
Dr. McKinnell s departure as principal officer in a subsequent filing
on Form 8-K.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits
Exhibit 99
Press Release of Pfizer Inc., dated July 28, 2006
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized undersigned.
PFIZER INC.
By: /s/ Margaret M. Foran
Margaret M. Foran
Title: Senior Vice President-Corporate
Governance, Associate General Counsel and Corporate Secretary
Dated: August 3, 2006
EXHIBIT INDEX
Exhibit No.
Description
99
Press Release of Pfizer Inc., dated July 28, 2006.